Is Johnson & Johnson a Good Dividend Stock to Buy Now?
For decades, Johnson & Johnson (JNJ 6.21%) stock was favored by investors seeking steady gains. Looking at its post-COVID-19 performance, though, steady gains aren't what investors received.
Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?
JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.
This Stock Has Increased 4,720%: Here's Why It's Still a Buy
Time is one of investors' greatest allies. With enough patience, even a relatively small sum of money invested in an excellent company can yield substantial returns, especially when dividends are r...
Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson JNJ will release earnings results for the second quarter, before the opening bell on Wednesday, July 16.
2 Dividend Stocks to Double Up on Right Now
No matter what the market is doing, one specific type of stock always will reward you -- and you don't have to lift a finger. This may sound too good to be true, but it actually isn't.
Johnson & Johnson's Outlook Clouded By $2 Billion Headwind
Johnson & Johnson JNJ is set to release its second-quarter earnings on Wednesday, July 16. According to Benzinga Pro data, analysts estimate adjusted earnings of $2.68 per share and sales of $22.85...
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based ap...
3 Must-Buy Dividend Stocks if You Only Have $5,000 to Spend
The vast majority of investors don't have hundreds of thousands to bet on each stock.
2 Bulletproof Dividend Stocks to Buy in July
While a high dividend yield is attractive, the consistency makes a stock worth holding.
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate d...
The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or prednisolone compared to a current standard of ca...
Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It.
Johnson & Johnson (JNJ -0.18%) is an iconic U.S. healthcare giant. It has changed over the years, but today its focus is on pharmaceuticals and medical devices.
Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential
Johnson & Johnson is a stable, dividend-growth powerhouse with 62 years of increases and a 3.44% forward yield, ideal for conservative, long-term investors. Despite recent legal headwinds and flat ...
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
Related Companies